CA
NZ
UK
AU
IND
US
Moderna, Inc. (NASDAQ:MRNA) shares surged after the company and Merck jointly announced on August 19, 2026 that the Phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival. The trial enrolled 1,137 patients with …
Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine developer, rose roughly 5.87% on August 20, 2026, moving to within about 2.6% of its 52-week high. The specific move does not appear to be tied to a distinct same-day Vaxcyte press release; rather, it coincides with a …
Repligen Corporation (NASDAQ:RGEN) jumped roughly 6% on August 19-20, 2026, after Moderna and Merck reported that their Phase 3 INTerpath-001 trial of the personalized mRNA melanoma vaccine intismeran autogene, combined with Keytruda, met its primary endpoint of recurrence-free survival in patients with resected stage …
CG Oncology, Inc. (NASDAQ:CGON) rose about 5.75% on August 20, 2026, pushing shares to essentially a fresh 52-week and all-time high near $80.68. The move builds on the July 27, 2026 publication of Phase 3 BOND-003 Cohort C results in The Lancet Oncology, evaluating …
MiMedx (NASDAQ:MDXG) shares are down 6.29% in pre-market trading on August 20, diverging sharply from a broadly firm healthcare sector, as investors digest recent developments including the definitive merger agreement to acquire Sanara MedTech and last week's mixed second-quarter results.
Moderna (NASDAQ:MRNA) shares are down 9.57% in pre-market trading on August 20, retreating roughly 10% from Wednesday's record close of $174.38, as investors take profits following the stock's historic single-day surge of 176.97%.
Ultragenyx Pharmaceutical (NASDAQ:RARE) shares are up 9.48% in pre-market trading on August 20, extending Tuesday's 2.94% gain, after the FDA granted accelerated approval for GENGLYCOS, the company's first-ever gene therapy approval and fifth overall product approval.
Edesa Biotech (NASDAQ:EDSA) shares are sliding in Thursday's pre-market session after the company priced a public offering late Wednesday, August 19. The deal consists of 3,870,500 common shares (or pre-funded warrants in lieu thereof for some investors, covering up to 675,000 shares) sold at …
Modular Medical (NASDAQ:MODD) shares are extending a multi-week advance tied to the company's push toward commercialization of its Pivot insulin delivery system. On August 3, 2026, the company announced it would begin its first commercial launch phase in October 2026 across five U.S. markets …
OSR Health (NASDAQ:OSRH), a Nasdaq-listed healthcare holding company, saw its shares fall about 29.4% in pre-market trading on August 20, 2026, to $0.2633 from a prior close of roughly $0.3731. The move extends a decline that began in earnest on August 19, when Nasdaq …
Please wait processing your request...